Oncorus, Inc. (ONCR)

$1.18

+0.02 (+1.72%)
Rating:
Recommendation:
-
Symbol ONCR
Price $1.18
Beta 0.000
Volume Avg. 0.14M
Market Cap 30.543M
Shares () -
52 Week Range 1.03-17.79
1y Target Est -
DCF Unlevered ONCR DCF ->
DCF Levered ONCR LDCF ->
ROE -50.39% Strong Sell
ROA -39.58% Strong Sell
Operating Margin -
Debt / Equity 54.53% Buy
P/E -
P/B 0.27 Neutral
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest ONCR news


Dr. Mitchell H. Finer
Healthcare
Biotechnology
NASDAQ Global Market

Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. The company has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. Oncorus, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.